Abstract:Nucleic acid-based therapy has emerged as a revolutionary methodology for treatment of the diseases related to protein dysfunction; however, lack of systemically applicable synthetic delivery systems limits its current usage in local applications, particularly for DNA-based therapy with regard to the poor bioavailability in the systemic administrations. To overcome this obstacle, we compiled multiple chemistry-based strategies into the manufacture of the gene delivery formulations to pursue improved tolerability of DNA to the enzymatic degradation in the biological milieu and prolonged retention in the systemic circulation. Here, we constructed a distinctive multilayered functional architecture: plasmid DNA (pDNA) was electrostatically complexed with cationic poly(lysine) (polyplex) as the interior pDNA reservoir, which was further cross-linked by redox-responsive disulfide cross-linking to minimize the occurrence of polyplex disassembly through exchange reaction with the biological charged,components. Still, the pDNA reservoir was spatially protected by a sequential thermoresponsive poly(N-isopropylacrylamide) palisade as the intermediate barrier and a biocompatible hydrophilic poly(ethylene glycol) (PEG) shell with the aim of preventing the accessibility of the biological species, particularly the nuclease degradation to the pDNA payload. Subsequent investigations validated the utilities of these strategies in accomplishing prolonged blood retention. In an attempt to apply this method for tumor therapy, ligand cyclic (Arg-Gly-Asp) peptide was attached at the distal end of PEG, validating prompted tumor-targeted delivery and gene expression of the loaded antiangiogenic gene at the targeted tumor cells and accordingly exerting antiangiogenesis of the tumors for abrogation of tumor growth. Together with its excellent safe profile, the proposed formulation suggests potential utility as a practical gene delivery system for treatment of intractable diseases.

The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma.

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma

Myristic acid-conjugated polyethylenimine for brain-targeting delivery: in vivo and ex vivo imaging evaluation.

Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.

Myristic acid-conjugated polyethylenimine for brain-targeting delivery:<i>in vivo</i>and<i>ex vivo</i>imaging evaluation

Targeted Gene Delivery to Glioblastoma Using a C-end Rule RGERPPR Peptide-Functionalised Polyethylenimine Complex

Enhanced Blood-Brain Barrier Penetration and Glioma Therapy Mediated by A New Peptide Modified Gene Delivery System

Retro-inverso CendR peptide-mediated polyethyleneimine for intracranial glioblastoma-targeting gene therapy.

Cyclic RGD-polyethylene Glycol-Polyethylenimine for Intracranial Glioblastoma-Targeted Gene Delivery.

Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration.

A bacteria deriving peptide modified dendrigraft poly-l-lysines (DGL) self-assembling nanoplatform for targeted gene delivery.

Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo.

Cyclic RGD-poly(ethylene Glycol)-Polyethyleneimine is More Suitable for Glioblastoma Targeting Gene Transferin Vivo

An MSN-PEG-IP Drug Delivery System and IL13Rα2 As Targeted Therapy for Glioma.

Polyethylenimine and Minicircle DNA Based Gene Transfer

PEI-Coated Fe₃O₄ Nanoparticles Enable Efficient Delivery of Therapeutic siRNA Targeting REST into Glioblastoma Cells

Targeted Delivery Of A Novel Palmitylated D-Peptide For Antiglioblastoma Molecular Therapy

Antitumoral Cascade-Targeting Ligand for IL-6 Receptor-Mediated Gene Delivery to Glioma

Glutathione-Sensitive Rgd-Poly(Ethylene Glycol)-Ss-Polyethylenimine for Intracranial Glioblastoma Targeted Gene Delivery

Plasmid Porf-Htrail Targeting to Glioma Using Transferrin-Modified Polyamidoamine Dendrimer